Assessment of interleukin‑10 level and Janus kinase 2 V617F mutation incidence in patients with primary myelofibrosis

Abstract

BACKGROUND: Myelofibrosis (MF) is largely documented by an abnormal cytokine expression, which in turn couldcontribute to bone marrow fibrosis, angiogenesis, and constitutional symptoms. To gain additional pathogeneticinsight regarding cytokine phenotype correlations in MF, this study estimated the level of interleukin‑10 (IL‑10)abnormality and Janus kinase (JAK2 V617F) mutation in primary MF.OBJECTIVE: The objective of this study was to assess serum IL‑10 level and it’s relation with the presence ofJAK2 V617F mutation in patients with MF.MATERIALS AND METHODS: JAK2 V617F mutation detection was performed in 32 patients with MF usingamplification refractory mutation screening‑polymerase chain reaction. IL‑10 level was estimated in 36 patientswith MF using enzyme‑linked immunosorbent assay technique compared to 27 healthy controls who wereenrolled for comparison.RESULTS: The study showed higher significant (P ≤ 0.002) increase of IL‑10 in patients with MF with cutoffvalue ≥8.9510 pg/ml and area under the curve value of 0.749 (P < 0.001) and also in patients with serum levelof IL‑10 more than 13.6 pg/ml characterized with significant lower white blood cell count, nonsignificant differencewith lower hemoglobin level, normal platelet count, and smaller size splenomegaly. About 59% of the studiedprimary MF (PMF) patients had JAK2 positive, 63% of them were male. There was no significant correlationbetween IL‑10 and JAK2.CONCLUSION: JAK2 mutation and IL‑10 as anti‑inflammatory cytokines may play a role in the pathogenesis andhematological presentation of patients with PMF. High IL‑10 level may predict good prognosis in patients with PMF.